News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Nvidia announced a $279 billion strategic investment, expanding its data-center addressable market and prompting buy recommendations.
  • PepsiCo fell to $137.75, yields about 4.2%, and is recommended as a patient dividend buy amid margin pressure.
  • Zeta Global beat and raised, grew revenue 43.5% and lifted 2026 guidance to ~$1.82B, supporting a buy-on-dip thesis.
  • Grab reported strong Q2, raised full-year guidance, and is positioned for a growth-phase trade below its 52-week high.
  • Lockheed Martin has a record ~$230B backlog and robust cash flow, making it a tactical buy while hedging for execution risk.
  • Zhihu proposed a RMB1.5 billion subscription to an AI-focused investment fund pending shareholder approval.

Latest Articles

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

SELLAS Life Sciences announced that three preclinical studies evaluating their CDK9 inhibitor SLS009 in pancreatic ductal adenocarcinoma (PDAC) models will be presented at the 2026 AACR Conference. These studies, conducted in collaboration with University of Wisconsin, explore novel therapeutic approaches involving SLS009 alone and in combination, …

Definitive Healthcare Appoints Clay Ritchey as CEO

Definitive Healthcare Appoints Clay Ritchey as CEO

Definitive Healthcare Corp. announced the appointment of Clay Ritchey as CEO effective September 8, 2026, succeeding Kevin Coop. Ritchey brings over 25 years of leadership experience in healthcare data and technology and plans to drive faster growth and innovation, leveraging AI integration into their healthcare commercial intelligence solutions.

Dell’s $95B AI Backlog Rewrites the Infrastructure Playbook

Dell’s $95B AI Backlog Rewrites the Infrastructure Playbook

Dell reported blockbuster results and a $95 billion AI server backlog on 09/01/2026. That backlog gives revenue visibility rare in enterprise hardware and justifies paying up for growth today. This trade idea proposes a swing long with a clear entry at $463.00, a stop at $435.00 and a target of $520.00 over the next 45 trading days, balanced agains…

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc Ltd., via its subsidiary NeuroThera Labs, is pursuing FDA Orphan Drug Designation for SCI-110, a cannabinoid-based treatment for adult Tourette Syndrome. To support regulatory and market access efforts, NeuroThera has engaged RK Strategies, a U.S. public affairs firm. SCI-110 has shown promising early clinical results and is now in Phase I…

GlobalFoundries and RAAAM Memory Technologies announce the joint development of next-generation GCRAM technology and test chip on FDX platform

GlobalFoundries and RAAAM Memory Technologies announce the joint development of next-generation GCRAM technology and test chip on FDX platform

GlobalFoundries and RAAAM Memory Technologies have successfully taped out a Gain-Cell RAM (GCRAM) test chip on GlobalFoundries' FDX FD-SOI platform. This collaboration aims to deliver higher-density, lower-power on-chip memory solutions optimized for edge AI, automotive, and IoT markets. The new memory technology offers significant area and power s…

U.S. P&C Insurers Post Strong Underwriting Gains Through First Half of 2026; Line-Specific and Geographic Challenges Persist

U.S. P&C Insurers Post Strong Underwriting Gains Through First Half of 2026; Line-Specific and Geographic Challenges Persist

Verisk and the American Property Casualty Insurance Association report a $31.7 billion net underwriting gain for the U.S. property/casualty insurance industry in the first half of 2026, driven by improved profitability and higher investment income despite ongoing challenges with catastrophe exposure and casualty lines. The industry's policyholders'…

Credo Technology Shares Drop After Q1 Results Spur Concern Over Margins

Credo Technology Shares Drop After Q1 Results Spur Concern Over Margins

Credo Technology’s stock plunged in pre-market trading after quarterly results that beat top-line and adjusted EPS estimates were accompanied by a notable decline in GAAP gross margin and cautious near-term margin signals. While management reiterated ambitious optical revenue targets and robust full-year growth guidance, investors reacted to margin…

Maris Tech Announces a 194% Increase in Company Revenues for the First Half 2026, Totaling Approximately $2.1 Million

Maris Tech Announces a 194% Increase in Company Revenues for the First Half 2026, Totaling Approximately $2.1 Million

Maris-Tech Ltd., a Nasdaq-listed Israeli company specializing in video and AI-based edge computing technology for defense and aerospace sectors, announced a 194% increase in revenue to approximately $2.1 million for the first half of 2026. Despite this strong revenue growth, the company reported a net loss of $2.8 million compared to net income of …

IHG Shares Jump After UBS Upgrade and Price-Target Lift

IHG Shares Jump After UBS Upgrade and Price-Target Lift

InterContinental Hotels Group PLC stock climbed after UBS upgraded the shares to Buy and raised its price target, pointing to a valuation gap versus peers, compressed EV/EBITDA relative to history, and stronger-than-expected first-half results. Management also continued buybacks, while the broader UK market traded lower amid geopolitical tensions a…

China Says It Does Not Seek Trade Surplus, Urges Domestic Demand and Openness

China Says It Does Not Seek Trade Surplus, Urges Domestic Demand and Openness

China's central bank governor told the G20 Finance Ministers and Central Bank Governors meeting that Beijing does not intentionally aim for a trade surplus and will pursue greater domestic demand alongside continued openness. The governor attributed worsening global trade imbalances to rising protectionism, the broad application of national securit…

Annexon to Participate in Upcoming September Investor Conferences

Annexon to Participate in Upcoming September Investor Conferences

Annexon, Inc. announced that its CEO, Douglas Love, will participate in several investor conferences in September 2026, including events hosted by Wells Fargo, Cantor Global Healthcare, and H.C. Wainwright. The company focuses on developing targeted immunotherapies for neuroinflammatory diseases by inhibiting the classical complement pathway. Live …

Nasdaq Completes Acquisition of Dasseti, Deepening Nasdaq eVestment's AI and Private Markets Capabilities

Nasdaq Completes Acquisition of Dasseti, Deepening Nasdaq eVestment's AI and Private Markets Capabilities

Nasdaq has completed its acquisition of Dasseti, an AI-powered platform specializing in due diligence and monitoring for investment consultants and institutional investors. Integrating Dasseti's technology into Nasdaq eVestment will extend the platform's coverage and improve efficiency in manager research, due diligence, and monitoring, especially …

Geron to Present at Upcoming Investor Conferences

Geron to Present at Upcoming Investor Conferences

Geron Corporation, a hematology-focused biopharmaceutical company, announced the participation of its management team in upcoming 2026 healthcare investment conferences. The company will discuss their drug RYTELO® (imetelstat), currently approved for lower-risk myelodysplastic syndromes, and ongoing pivotal Phase 3 trials in myelofibrosis and other…